Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 6:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Tesamorelin Clear all
Completed Phase 2 Interventional Results available

Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons

NCT02572323
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Tesamorelin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
4
States / cities
Los Angeles, California • Palm Springs, California • San Diego, California + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 5, 2026, 6:26 AM EDT
Completed Phase 3 Interventional

TH9507 in Patients With HIV-Associated Lipodystrophy

NCT00123253
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
TH9507
Drug
Lead sponsor
Theratechnologies
Industry
Eligibility
18 Years to 65 Years
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
35
States / cities
Los Angeles, California • Palm Springs, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Sep 5, 2026, 6:26 AM EDT
Completed Not applicable Interventional Results available

Tesamorelin Effects on Liver Fat and Histology in HIV

NCT02196831
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
Interventions
tesamorelin, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Bethesda, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 5, 2026, 6:26 AM EDT
Completed Phase 3 Interventional Results available

TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy

NCT00608023
View directory record Official record
Conditions
Lipodystrophy, HIV Infections
Interventions
Tesamorelin, Placebo for Tesamorelin
Drug
Lead sponsor
Theratechnologies
Industry
Eligibility
18 Years to 65 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Indio, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Sep 5, 2026, 6:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

SMART: Somatotrophics, Memory, and Aging Research Trial

NCT00257712
View directory record Official record
Conditions
Aging, Mild Cognitive Impairment
Interventions
TH9507 human growth hormone releasing hormone (GHRH)
Drug
Lead sponsor
University of Washington
Other
Eligibility
55 Years to 90 Years
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 5, 2026, 6:26 AM EDT
Completed Not applicable Interventional Results available

Effects of Short-term Growth Hormone in HIV-infected Patients

NCT00795210
View directory record Official record
Conditions
HIV Lipodystrophy
Interventions
Growth hormone, Growth Hormone Releasing Hormone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Sep 5, 2026, 6:26 AM EDT
Terminated No phase listed Observational

Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®

NCT01579695
View directory record Official record
Conditions
HIV
Interventions
Tesamorelin for injection
Drug
Lead sponsor
Theratechnologies
Industry
Eligibility
18 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
31
States / cities
Bakersfield, California • Fountain Valley, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Sep 5, 2026, 6:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men

NCT00850564
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Growth Hormone Releasing Hormone (Tesamorelin)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Sep 5, 2026, 6:26 AM EDT
Terminated Phase 4 Interventional Results available

Body Composition and Adipose Tissue in HIV

NCT03226821
View directory record Official record
Conditions
HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition
Interventions
Tesamorelin
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 68 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 5, 2026, 6:26 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue

NCT01632592
View directory record Official record
Conditions
Abdominal Obesity
Interventions
Tesamorelin, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Sep 5, 2026, 6:26 AM EDT
Completed Not applicable Interventional Results available

Effects of Growth Hormone Releasing Hormone in HIV

NCT01263717
View directory record Official record
Conditions
HIV, HIV Lipodystrophy
Interventions
tesamorelin, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2017 · Synced Sep 5, 2026, 6:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment

NCT02553603
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Growth Hormone Releasing Hormone (GHRH), Placebo Growth Hormone Releasing Hormone
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
55 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Sep 5, 2026, 6:26 AM EDT
Completed No phase listed Observational

Growth Hormone Dynamics and Cardiac Steatosis in HIV

NCT03826160
View directory record Official record
Conditions
Human Immunodeficiency Virus, Lipodystrophy, Cardiac Disease
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 70 Years
Enrollment
23 participants
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Sep 5, 2026, 6:26 AM EDT
Completed Phase 2 Interventional Results available

Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk

NCT03375788
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Obesity, Obesity, Abdominal, Liver Fat, Fatty Liver
Interventions
Tesamorelin, Identical Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Sep 5, 2026, 6:26 AM EDT
Recruiting Phase 2 Interventional

Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury

NCT03150511
View directory record Official record
Conditions
Peripheral Nerve Injuries
Interventions
Tesamorelin 2 Milligrams (MG)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 5, 2026, 6:26 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese

NCT00675506
View directory record Official record
Conditions
Abdominal Obesity, Growth Hormone Deficiency
Interventions
Growth hormone releasing hormone (GHRH) 1-44, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 5, 2026, 6:26 AM EDT
Withdrawn No phase listed Observational

Egrifta Replacement and Sleep Disordered Breathing

NCT01788462
View directory record Official record
Conditions
Lipodystrophy
Interventions
Tesamorelin (Egrifta)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 5, 2026, 6:26 AM EDT
Recruiting Phase 2 Interventional

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV

NCT06554717
View directory record Official record
Conditions
HIV-1-infection, Frailty, Impaired Physical Function, Abdominal Obesity, Aging
Interventions
Tesamorelin, Placebo, Exercise
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 5, 2026, 6:26 AM EDT
Terminated Phase 4 Interventional

Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®

NCT01591902
View directory record Official record
Conditions
Diabetic Retinopathy, HIV
Interventions
Tesamorelin, Placebo-Control
Drug
Lead sponsor
Theratechnologies
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
24
States / cities
Phoenix, Arizona • Los Angeles, California • Palm Springs, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Sep 5, 2026, 6:26 AM EDT